Epitomee Medical Ltd - Asset Resilience Ratio
Epitomee Medical Ltd (EPIT) has an Asset Resilience Ratio of 0.24% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Epitomee Medical Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Epitomee Medical Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Epitomee Medical Ltd.
Liquid Assets Composition Over Time
This chart breaks down Epitomee Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Epitomee Medical Ltd (EPIT) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA87.57K | 0.24% |
| Total Liquid Assets | ILA87.57K | 0.24% |
Asset Resilience Insights
- Limited Liquidity: Epitomee Medical Ltd maintains only 0.24% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Epitomee Medical Ltd Industry Peers by Asset Resilience Ratio
Compare Epitomee Medical Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
TransMedics Group Inc
NASDAQ:TMDX |
Medical Devices | 0.00% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581 |
Medical Devices | 18.80% |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580 |
Medical Devices | 10.74% |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273 |
Medical Devices | 34.29% |
Annual Asset Resilience Ratio for Epitomee Medical Ltd (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Epitomee Medical Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.84% | ILA20.04 Million ≈ $53.73K |
ILA40.21 Million ≈ $107.81K |
-14.97pp |
| 2022-12-31 | 64.81% | ILA35.78 Million ≈ $95.92K |
ILA55.20 Million ≈ $147.99K |
-- |
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.